1. Introduction {#s0005}
===============

Focal cortical dysplasia (FCD), as recognized by Taylor, Bruton, Falconer and Corsellis is a unique type of lesion in epilepsy pathology ([@bb0265], [@bb2500]). Taylor\'s focal cortical dysplasia, i.e. *FCD II A* and *B* according to current histopathological classifications ([@bb0060]), is characterized by pathognomonic tissue features of dysplastic neurons often accompanied by "balloon cells" ([@bb0065], [@bb0015], [@bb0265]). A large body of evidence has shown that FCD II has an intrinsic epileptogenic potential: epileptic discharges do arise from the lesion itself as shown by lesional samplings with subdural, electrocorticographic and intracerebral recordings ([@bb0115], [@bb0220], [@bb0100]), single cell electrophysiological techniques ([@bb0090]), as well as previous data using magnetoencephalography (MEG) (Morioka 1999, Bast 2004, [@bb0305], Ishii, 2008, [@bb0255], [@bb0310], [@bb0295]). Overlap of irritative zones and seizure onset zones has been reported for FCD in high rates ([@bb0020]). Extratemporal epileptogenic zones prevail in FCD II due to predilection for cortical areas outside the temporal lobes ([@bb0065], [@bb0135], [@bb0015]), predominating in frontal and pericentral localisations ([@bb0270]). Accordingly, seizure semiology often appears complex and surface EEG recordings may not show localized epileptic discharges or ictal patterns at all. Epilepsy surgery offers good chances for FCD II patients ([@bb0235]), but localizing the epileptogenic zone and surgery is a challenge in FCD II ([@bb0135], [@bb0130]) since lesions often reside in close relation to eloquent cortex and lesion borders are not exactly defined by MRI ([@bb0260]). Currently, many FCD II lesions are visualized presurgically by optimized magnetic resonance imaging (MRI) ([@bb0270], [@bb0285], [@bb0175]). However, when subtle and small, then often residing within deep parts of cerebral sulci ([@bb0040]), FCD II can escape visual MRI analysis even at experienced referral centers ([@bb0035], [@bb0280]). FCD II likely represents the most frequent cause of "nonlesional" focal epilepsy ([@bb0035], [@bb0070]). Sophisticated MRI postprocessing methods have been developed in order to increase FCD II detection rates after normal MRI readings ([@bb0175], [@bb0035], [@bb0285], [@bb0145], [@bb0010], [@bb0030]) including the morphometric analysis program (MAP, [@bb0145]). Since MRI/MAP results represent pure structural information and may provide false positive findings ([@bb0145]), supporting concordant evidence from other data including methods depicting epileptogenicity is needed in order to plan an epilepsy-surgical strategy. We here will demonstrate high efficacy and accuracy of magnetoencephalography (MEG) in FCD II and argue for surgically targeting the MEG-MRI-lesion, for this seems to facilitate excellent results.

2. Patients and methods {#s0010}
=======================

Patients were selected from the database of the epilepsy surgery program at Erlangen Epilepsy Center, Friedrich-Alexander University Erlangen-Nuremberg, Germany. All patients had been investigated for pharmacoresistant focal epilepsy from 2006 to 2016 in order to determine eligibility for epilepsy surgery. Patients selected for this study had either a histopathological verified diagnosis of FCD II and/or characteristic MRI signs of FCD II. MRI criteria were: focal cortical thickening, grey-white matter blurring, white matter signal increase and/or transmantle sign ([@bb0285]). In addition to comprehensive epilepsy workup ([@bb0165]) including non-invasive-video-EEG, MRI imaging and neuropsychological testing, all patients had received a MEG using the same whole-head system (see [Methods](#s0010){ref-type="sec"}). A total of 21 patients were included in the study. Selected patients had invasive recordings in advance to resective surgery (*n* = 14). All surgical patients had a follow up of at least 1 year.

2.1. MRI acquisition and morphometric analysis (MAP) {#s0015}
----------------------------------------------------

High resolution MRI imaging had been performed using a 3 T Magnetom Trio (Siemens Medical Solutions, Erlangen Germany) with a 32 channel head coil. Sequences included the following: 1) FLAIR (3D-FLAIR, 1 × 1 × 1 cm; TR 4000, TE 388, matrix 258 × 256), 2) T1 magnetization prepared rapid gradient echo (MPRAGE, 1 × 1 × 1cm, TR 2300, TE 2.98, matrix 256 × 256). 3D MPRAGE sequences were used to perform morphometric analysis using the MAP software (morphometric analysis program) by [@bb0145]. The software compares an individual patient\'s structural MRI to a scanner-specific database of normal controls. Distribution of grey and white matter is analyzed voxel-wise and yields maps of selected feature parameters of cortical thickness and grey-white boundary sharpness highlighting typical signs of FCD ([@bb0145]). All feature maps are also combined into a "combined z-score" map. Only these combined-z-score maps were used for statistical evaluation in the presented study. Anatomical lesion localizations were rated visually and categorized according to Wang ([@bb0295]). We depicted the FCD by using MAP at a z-score threshold \> 3 in order to calculate distances between the MEG source localization (see below) and the FCD. Identification of the real FCD was validated based on postsurgical diagnosis and the synopsis of all available findings (i.e. video-EEG, semiology, imaging).

2.2. MEG acquisition and analysis {#s0020}
---------------------------------

MEG was acquired using a whole-head 248 channel magnetometer system for patient investigations after 2010 (Magnes 3600WH, 4D-Neuroimaging, San Diego, CA, USA) and a two sensor gradiometer system with 2 × 37 channels before (Magnes II, 4D-Neuroimaging). Duration of recordings varied depending on the clinical needs and respective investigation, e.g. for functional mapping and/or epileptic focus localization. Recordings were conducted in supine position. Patients were asked to keep their eyes closed. If they fell asleep, they were not woken up before of the end of the complete recording. With the Magnes 3600WH system, data were acquired using a sample rate of 508 Hz and an analogue 0.1 Hz high pass filter. Noise reduction was performed offline, taking reference gradiometers and magnetometers into account (manufacturer\'s software). Recordings with the Magnes II system utilized a sample rate of 520 Hz, an analogue 1 Hz high pass filter and no offline noise reduction. For analysis, an additional digital 1--70 Hz and a 50 Hz notch filter were applied. Epileptic discharges were manually identified and selected by an experience reviewer (SR). Subsequently, all identified patterns were averaged and submitted to source analysis utilizing single moving dipole localization in spherical volume conductors (Curry 7, Compumedics Neuroscan, Singen, Germany). All patients only presented with a single focal type of spike, i.e. a subclassification of spikes into groups with similar topography and morphology was not necessary. Channels for analysis were restricted to 37 channels centered on the steepest gradient at the spike peak using data from Magnes 3600WH. Dipole localization methodology with both systems was thus comparable. This approach, suggested by the system manufacturer and also used in other studies ([@bb0245]) removes channels distant from the maximal gradient, which contain mostly unrelated data, thus improving the appropriateness of a single dipole model for source analysis. Only resulting dipoles with deviation between measured and modelled field of \<30% were analyzed further. The single best dipole per patient in terms of minimal deviation was superimposed on individual 3D MP-RAGE MRI, and MAP. If two dipoles resulted in equal deviation, the earlier was used.

2.3. Analysis of spatial relationship between MEG-source, MAP-lesion and postOP-situs {#s0025}
-------------------------------------------------------------------------------------

Both MEG and MAP utilize the same 3D MP-RAGE dataset as part of their respective workflow for visualization of MEG localizations and as a basis for computation of statistical MAP maps. Standard coregistration procedures for MEG using fiducials at the nasion and the left and right preauricular point were applied. MEG results were displayed on MAP maps using Curry 7 software. Concordance of MEG results and MAP findings were compared on a sublobar level using a classification scheme according to [@bb0295] and [@bb0155], which included the following regions: frontopolar, dorsolateral frontal (superior), dorsolateral frontal (inferior), mesial frontal, anteroparietal, posteroparietal (superior), posteroparietal (inferior), mesial parietal, lateral occipital, mesial occipital, temporopolar, lateral temporal, mesial (neocortical) temporal, anterior insular, posterior insular, anterior cingulate, posterior cingulate and central area (see [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}). In patients with epilepsy surgery, the relation of MEG localizations, MAP finding and resection cavity was evaluated using postoperative MR images, which were acquired either immediately after the resection using intraoperative 1.5 T MRI ([@bb0240]) or 3 T MRI at 6 months after surgery. Patient 15 had to be excluded from this analysis, since although undergoing epilepsy surgery, postoperative MRIs were not available. The degree of resection was evaluated visually: The MEG localization was considered to be resected completely, if it was located within the resection volume. It was classified as partially resected if the localization was located at the border of the resection (within 2 cm) and not resected if otherwise. Resection extent of MAP findings was related to MAP above the significance threshold of z \> 3 ("MEG marked MAP"). (See [Table 3](#t0015){ref-type="table"}.)Table 1Clinical summary.Table 1Part 1IDM/FHistologyAge ate sz onsetEpilepsy durationLesion siteSideBOSSemiology1FFCD IIA228Frontal lateralRightNoNo aura; Tonic arm left asymm. Tonic, versive to right; Rarely Tonic-clonic2FFCD IIB174Parietal postcentralLeftYesDysesthesia & paresis arm/hand right3Mn.a166FrontalLeftNoClonic right hand4FFCD IIA237Frontal G. front. MedRightNoVocalization, tachycardia, complex-motor (trunk and proximal muscles) from sleep5Fn.a1116PrefrontalLeftNoSomatosensory leg right evolving tt motor leg right, one initial TCS6Fn.a931PrefrontalLeftNoVersive to right7Fn.a622Frontal G. front. MedLeftYes(Unspecific aura), vocalization, complex-motor evolving to asymmetric tonic; most from sleep8MFCD IIB729Parietal postcentralLeftNoSomatosensory: haptic + cold-goose flash non-lateralized; in sleep: vocalization, blinking, complex-motor9FFCD IIB527Frontal lat-opercularRightNoNo aura, face grimacing, blinking; complex-motor; often ictal speech; evolution to tonic-clonic (versive left)10FFCD IIB723Temp-occ lateralRightNoHeadache + optic sensations + vomiting; accompanied by nystagmus/oscillopsia; +automotor in sleep; tonic-clonic: single11FFCD IIB1224Parieto-occipitalRightNoDysmnestic aura (visual-scenic), out-of-body experience; evolving to dialeptic; one initial TCS12FFCD IIA1712Frontal precentralLeftNoClonic right face; nocturnal hypermotor13MFCD IIB429Frontal G. front inf.RightNo(unspecific aura); nocturnal complex motor14MFCD IIA2423Parietal mesialLeftNoAssymetr. tonic, shouting; inconstant sensory right leg15FFCD IIB633InsularLeftNoHypermotor16MFCD IIB710FrontobasalRightNoAutonomic -- behavioural symtoms; ictal speech17Wn.a614Frontal lateral opercularRightYesCephalic aura - somatosensory arm left, complex-motor; no generalizations18WFCD IIB1329Frontal mesial, SSMARightYesComplex-motor from sleep19WFCD IIA126Frontal premotorLeftNoClonic right arm and assymmetric tonic20MFCD II nos417Parietal mesialRightYesSensory left leg and visual - assymetric tonic21WFCD IIB333Frontal dorsalLeftNoHypermotor from sleep and unspecific aurae during dayFCD = focal cortical dysplasia; FCD nos = FCD not otherwise specified (due to fragmented tissue); SSMA = supplementary sensomotor area.\
BOS = bottom-of-sulcus-FCD.  Part 2ID1st MRIreadSurface EEG spikesSurface EEG: ictal patternsInvasiveSurgeryAge at surgeryOutcome EngelTimepoint (months)1NegNoDecrement onlyYesYes323A242+NoDecrement evolving to pattern C3-P3YesYes211A243+NoNo patternn.aNoNo surgeryn.an.a4+Frequent C4, P4Rhythmic spikes F4 C4 or decrement followed by fast Beta C4, CzYesYes411C485+Frequent over midline Fz, CzFast activity midlineYesNoNo surgeryn.an.a6+F3-C3Rhythmic pattern C3-P3n.aNoNo surgeryn.an.a7+Rare, F3, FzRhythmic spikes f left F3, Fz preictally à Beta Fz F3 20 Hzn.aNoNo surgeryn.an.a8+Rare, left parietal P3, P5Left parietal P3, P5 12--14 HzYesYes361A609+Very rareNon lateralized decrementNoYes321A4810+Rare; periictally many occ-temp rightTemp-occ rNoYes331D4511+Par-occ rDecrement evolving to right par-occNoYes331A3612+NoNo patternYesYes291A3613(+)Frequent FP2, F4Right lateralYesYes331A4214NegF3-C3Fast activity C3, CzYesYes473A2415(+)Rare, left temporalCentrotemporal delta-then bilateralYesYes391B9116(+)FP2, F4None or frontal rightYesYes171B3617+Frequent F8 in sleepNo clear ictal patternNoNoNo surgeryn.an.a18NegNoNo patternYesYes421A3019(+)Sharp wave C3, CzSubclinical C3, Cz; clinical sz 50% without pattern; other fast C3-P3YesYes273A4820NegRare sharp wave P4, PzRhythmic sharp waves P4-C4-CzYesYes211A1821(+)Polyspikes F3, FP1Regional frontocentral leftYesYes361A12[^2][^3]Table 2Results of MR -- MAP -- MEG analysis.Table 2IDSideMR Location (Wang)MEG Location (Wang)Duration (min.)Spikes (number)Distance to real FCD (mm)1RightDLF inf.DLF inf.201014.52LeftDLF inf.DLF inf.12116.93LeftDLF sup.DLF sup.20620.64RightDLF inf.DLF inf.202217.85LeftDLF sup.DLF sup.2051.66LeftDLF sup.DLF sup.20521.87LeftDLF inf.DLF inf.202424.88LeftPPPP2058.79RightFP, AIAI201810.610RightLOLO20452.211RightAPAP205410.112LeftDLF sup.DLF sup.20126.313RightDLF inf.DLF inf.204911.714LeftPMPM2074.515LeftPIPI203312.216RightFPFP20889.617RightDLF inf.DLF inf.401114.518RightDLF sup.DLF sup.401412.219LeftFMn.an.a0n.a20RightFMPM405133.021LeftDLF sup.DLF sup40332.2Mean 28.1Mean 12.3[^4][^5]Table 3Resection of MEG/MAP - classification.Table 3IDMEG resectedMEG-marked MAP resected1NoPartial2PartialComplete3n.an.a4Complete(Complete)5n.an.a6n.an.a7n.an.a8CompletePartial9PartialComplete10CompleteComplete11PartialComplete12PartialPartial13CompleteComplete14NoNo15n.an.a16CompleteComplete17n.an.a18Complete(Complete)19n.an.a20NoComplete21CompleteComplete[^6]

2.4. Outcome {#s0030}
------------

Seizure outcome was scored according to Engel\'s classification at last available follow up.

2.5. Statistical analysis {#s0035}
-------------------------

Differences of MEG and MAP resection in patients with Engel 1 (completely or almost seizure free) versus Engel 2--4 (persisting seizures) outcomes were compared using Fisher\'s exact test. Sensitivity, specificity, positive and negative predictive values were calculated based on concordance of MEG localizations with the resection volume in seizure free patients vs. patients with persisting seizures. A localization was classified as a positive if the localization was within 2 cm of the resection (corresponding to complete or partial resection, see above), negative otherwise. Specificity thus is based on localizations outside this volume in patients with persisting seizures (Engel 2--4). Note that this approach may overestimate specificity ([@bb0230]). Differences of MEG distances to FCD between patients with BOS and other FCDs were evaluated using a *t*-test. Statistical analysis was performed using IBM SPSS Statistics 24.0 (Armonk, NY, USA).

3. Results {#s0040}
==========

3.1. Clinical data {#s0045}
------------------

Twenty-one patients were eligible for this study. Twelve patients showed a clear FCD II suspect lesion by conventional visual MRI inspection alone. In five patients, MAP analysis gave the main clue for FCD suspicion, and lesions were detected by visual MRI re-view. In four patients (patients 1, 14, 18, 20), FCD II was suspected on the basis of MAP mainly. 5 lesions were classified as bottom-of-sulcus dysplasia (BOS), i.e. patients 2, 7, 17, 18, 20 (see [Fig. 1](#f0005){ref-type="fig"} for illustrative examples). Lesions were localized as follows: frontal (14), parietal (4), parietooccipital (1), temporooccipital (1) and insular (1). Right/Left ratio was 10/11. Mean age at presurgical evaluation in this FCD II patient cohort was 31.1 years, mean epilepsy duration at time of evaluation was 22.5 years (range 4--37). Age at epilepsy onset ranged from 1 to 24 years (mean 8.5). Operated patients had a mean age at surgery of 32.4 years. One patient underwent surgery at another center (patient 15). Mean follow up time was 38.9 months. Seizures in all patients were reported as daily/multiple per day, the majority occurring from sleep, all but one patient had no secondary generalizations. Surface EEG recordings did not show any interictal spike-wave activity in five patients. Semiology contained helpful signs indicating at least hemispheric lateralization in fourteen patients. In seven patients, semiology was inconclusive for lateralization or lobe. Sixteen patients underwent resective epilepsy surgery, 14/16 after invasive recordings with subdural and/or depth electrodes. Two patients had a second surgery (patients 1 and 11), 3 and 7 years after the 1st surgery, respectively. Patient \#15 underwent surgery at another institution, data about resection extent were not available. Respectively, this patient was excluded for comparison of resection and seizure outcome. 81.3% (13/16) had excellent outcomes (Engel 1) at last follow up. Clinical data and findings of our patient group are summarized in [Table 1](#t0005){ref-type="table"}.Fig. 1Illustrative MRI examples from bottom-of-sulcus dysplasias (BOS), all FLAIR (see arrows); patient IDs as indicated.Fig. 1

3.2. Imaging results from MEG-MRI coregistration {#s0050}
------------------------------------------------

MEG analysis revealed a circumscript source localization of interictal activity in 20 of 21 patients (95.2%), one patient had no detectable spikes during the MEG session. Mean spike frequency during MEG-measurement was 29.9 per 20 min, all cases showed at least 5 spikes except for patient \#19 with no spikes. Source localizations as determined by MEG analysis had close spatial relationship to lesional sites as determined by MAP in all these 20 patients. The mean distance of dipole localization to outer border of MAP abnormality at the FCD site was 12.3 ± 8,1 mm, all but three values were below 20 mm. Distances to BOS FCDs were larger on average compared to other FCDs (18.3 vs. 9.0 mm, *p* = 0.025). Details are summarized in [Table 2](#t0010){ref-type="table"}, examples are illustrated in [Fig. 2](#f0010){ref-type="fig"}. In patient 10, a non-motor focal seizure occurred during MEG acquisition, suitable for source analysis of ictal hypersynchronous activity, illustrating close spatial relation of interictal and ictal sources ([Fig. 3](#f0015){ref-type="fig"}).Fig. 2**A/B** MEG-MRI and MEG-MAP coregistrations, illustrative examples. Upper rows: 3 lesional planes from 3D-FLAIR; Lower Rows: 3 corresponding planes from MAP; red dot indicates source localization from MEG, green cursor is focused on the FCD. A: patient 9; B: patient 8 (see [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}).Fig. 2Fig. 3Ictal (red dot) and interictal (blue dot) MEG sources in close proximity to each other and the lesion as illustrated in multiplanar FLAIR (upper row), and MAP (lower row); patient 10. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

3.3. MEG localizations versus resection cavities and surgical outcome {#s0055}
---------------------------------------------------------------------

Results of evaluating the resection of the MEG source are shown in [Tables 4 and 5](#t0020){ref-type="table"}. We included 14 of 16 operated patients in this analysis, since a single patient had no MEG source (patient 19) and in one patient postsurgical MRIs were unavailable (patient 15). When the MEG source was ranked resected, as well as when the MEG-marked MAP volume was ranked resected, patients showed better surgical outcomes according to Engel (*p* = 0.033 each, Fishers exact test). Sensitivity of MEG localizations for the resection in seizure free patients was 92% with a specificity of 100%. Positive and negative predictive value were 100% and 67%. Illustrative patients with persisting seizures after a surgery sparing the MEG source by 1st surgery are shown in [Fig. 4](#f0020){ref-type="fig"}, one patient achieving seizure freedom by 2nd surgery including the MEG source.Tables 4 and 5Resection of MEG sources versus seizure outcome.Tables 4 and 5MEG resectedNoPartiallyCompletelyFisher\'s exact testEngel 11470.033Engel \> 1200  MEG marked MAP maximum resectedEngel 102100.033Engel \> 1110Fig. 4**A/B.** MEG sources in relation to resection cavities in patients with two surgeries: A: patient 11; continuing seizures after 1st surgery, sustained seizure freedom after 2nd surgery years later. As illustrated, the 2nd surgery (lower row, intraoperative MRI) included the MEG-source, which had remained unresected by the 1st intervention; B: patient 1: persisting seizures after 2nd surgery, MEG source in unresected edge area despite large resection volume.Fig. 4

4. Discussion {#s0060}
=============

FCD II, also known as Taylor\'s focal cortical dysplasia, is a highly epileptogenic neocortical lesion ([@bb0065]; [@bb0015]). The FCD II related seizure disorder is often characterized by a pharmacoresistant course after early-life epilepsy onset and high seizure burdens with seizures predominating in sleep ([@bb0210], [@bb0215], [@bb2600]), strikingly illustrated also by our patient cohort (mean age at epilepsy onset 8.4 years; seizures multiple per day in all). Failure to visualize a lesion is a negative predictor of surgical success in epilepsy overall ([@bb0045]). Visualizing the lesion and defining lesion extent is a challenge in FCD II. Epilepsy surgery can achieve seizure freedom in a significant percentage of FCD II patients ([@bb0130], [@bb0050], Losurdo 2014, [@bb0235]). The crucial point is to reliably (i) detect FCD II as the underlying etiology in these epilepsies and (ii) identify the epileptogenic zone including its spatial relations to the structural lesion ([@bb0130], [@bb0185]). According to our study these goals can be supported by combining MRI, MRI post-processing, such as MAP, and MEG, as shown here by excellent surgical outcomes with 81.3% reaching Engel 1 compared to published series (for reference see [@bb0130]) including patients with prolonged duration of pharmacoresistant epilepsy. According to our data, targeting the MEG-source seems particularly successful in FCD II.

MEG analysis in our patient cohort demonstrated a close spatial relationship between MEG source and FCD II lesion with a circumscript source localization in the majority of patients, corroborating earlier studies reporting good sensitivity and localization accuracy for MEG in FCD II ([@bb0305], [@bb0150], [@bb0255], [@bb0310], [@bb0200], [@bb0290], [@bb0295]). In our cohort, MEG sensitivity was as high as 95.2% in FCD II, compared to 70% reported from unselected epilepsy series ([@bb0245]). Moreover, dipole localizations were within or close to the lesion site in our cohort, matching reports of very active and localized epileptogenicity for FCD II compared to other etiologies ([@bb0220], [@bb0195], [@bb0025], [@bb0150], [@bb0055]). MEG-MAP analysis in this study was facilitated by preselecting patients with clear-cut FCD II, validated by classic MRI and histopathology in most cases. Interestingly, the MEG source was not constantly found in the center or within the MR lesion, but rather next to edge areas. Of note in this context is that tissue extent in FCD II has been shown to exceed the area of MRI visible lesion, with dysmorphic neurons beyond the borders of the MRI lesion ([@bb0260]). Areas of signal increase in FLAIR seem to correlate to balloon cell rich parts of the FCD, which in turn are more likely to be electrically silent ([@bb0090]; [@bb0100]). Therefore, our observation still is compatible with an intralesional MEG-source. The close proximity of MEG sources to the FCD site in our cohort are contrasted by a recent study describing also more remote MEG clusters in some patients, especially concerning small BOS FCDs ([@bb0205]). These authors suggest closed-field effects due to the random orientation of neurons within the FCD, low density of neural cells and small sizes of especially BOS FCDs as potential reasons for remote localizations due to lower signal-to-noise ratios (SNR). Furthermore, they used single moving dipole analysis of single spikes ([@bb0205]). As a consequence, noise and ongoing, unrelated background activity likely had a stronger impact on the results as our averaged spike approach, which provides and overall better SNR ([@bb0025]). Whereas distances between MEG and the lesion were significantly different between BOS and non-BOS FCDs, BOS FCDs also showed closely related MEG-sources in our study. We also utilized local channel groups centered on the gradient of interest, which further excludes unrelated activity, e.g. in contralateral sensors. The combination of these two strategies may provide access especially to early components of the activity, which may not have propagated as much from the sources in or close to the FCDs. Epileptogenic areas in terms of both interictal irritative zones and ictal onset zones in FCD II are closely related ([@bb0020]), as illustrated by our patient 10, where source localizations of interictal spiking as well as seizure onset were highly concordant ([Fig. 3](#f0015){ref-type="fig"}), again illustrating *intrinsic epileptogenicity* for FCD II ([@bb0090], [@bb0195], [@bb0115], [@bb0225]).

Recently, some reports already did imply a potential for combining different diagnostic approaches in FCD II including MRI/MAP, MEG and depth stereo EEG (SEEG): Implantation of a depth electrode into a patient\'s MAP-lesion, located within a neocortical compartment suggested by semiology, led to good localizing data and successful surgery ([@bb0300]). In another FCD II patient receiving invasive recordings with *simultaneous* MEG as a final step of evaluating a MAP lesion, localizing data were highly concordant ([@bb0290]). Histopathological workup in both cases revealed FCD II and seizure freedom achieved ([@bb0300]; [@bb0290]). In another series, resection of "densely clustered" MEG sources in MRI-negative cases related to a postsurgical histopathology of underlying FCD II in some patients and achieved good outcomes ([@bb0310]). In further three patients, MEG was highly concordant to the localization of occult FCD II in insular epilepsy ([@bb0140]). Indeed, patient 3 from the latter study is identical to patient 15 in our cohort. Another recent study also reported on linking MAP and MEG data in FCDs ([@bb0295]). In these studies, MAP analysis had been performed in retrospect on preoperative MRIs from patients *after* surgery for MRI negative epilepsy in order to investigate the value of MAP results versus preOP-MEG data ([@bb0295]): while positive correlations between favourable seizure outcomes and complete resection of the MEG source and/or MAP lesion were reported ([@bb0295]), comparison to our series is difficult due to population heterogeneity in terms of pathology (only two cases of FCD II were included), epilepsy syndrome (high percentage of temporal lobe epilepsy), and \<50% of patients showing a MAP abnormality overall ([@bb0295]).

In the same way, a recent report on relationships between structural, magnetic source and stereo-EEG data in FCDs ([@bb0080]) did include very different epilepsies and lesions, but no FCD IIB respectively. According to our data, linking MRI and MEG offers a powerful tool in FCD II related epilepsy. We selected cases with clear-cut FCD II lesions, the majority proven by histopathology as "gold standard", since here lesions were expected to be shown by MAP. Our data show that combining MRI-postprocessing and MEG effectively provides accurate and concordant localizing data in a high percentage of FCD II related epilepsies. That a circumscript MEG-source can support better identification of a MRI-lesion during thorough imaging review has been demonstrated ([@bb0190], [@bb2700]). In a "MRI negative" scenario, therefore, a localized MEG source matching with an abnormality seen in MAP *only*, is likely to indicate underlying FCD II, especially in extratemporal epilepsy displaying certain clinical characteristics, e.g. frequent nocturnal seizures, at least in an adult cohort as ours. Automatization of this kind of analysis, however, might be difficult since MAP can display false positives and abnormal z-values outside the true FCD. Whether there are signal characteristics in MEG-data, that might specifically indicate underlying FCD II-pathology is an important aspect for future research.

Optimal planning of resective surgery and/or targeting intracranial electrode placement in FCD II so far largely relies on information *where* the lesion resides. MEG technology appears as an ideal tool for visualizing FCD II-related epileptogenicity: (i) MEG is noninvasive (ii) MEG shows excellent spatial and temporal resolution; (iii) MEG results can be coregistered to other individual data in three-dimensional space; (iv) MEG can detect epileptic activity even if surface EEG fails and (v) MEG can help predicting invasive EEG localization ([@bb0245], [@bb2800], [@bb0120], [@bb0160]; [@bb0250], [@bb0310], [@bb0125]). Overall, MEG coregistration is not difficult (see Methods). In contrast, surface EEG techniques may fail in FCD II: (i) extratemporal seizures often show a complex semiology without clearly localizing symptoms, (ii) surface EEG often lacks interictal epileptic activity or clear ictal seizure patterns ([@bb0100], [@bb0315]), at least when standard 10-20-EEG is considered. Therefore, invasive recordings are often chosen ([@bb0130]), and have been discussed to delineate the resective strategy in FCD II best ([@bb0095]). Incorporating MEG sources into surgical planning in our view could improve rates of surgical success in FCD II, as suggested by previous reports ([@bb0300], [@bb0140]), and offers potential to optimize but also *limit* the amount of invasive recording and resection volumes in the future by better targeting ([@bb0300]). An interesting target for future research would be to investigate (and compare to MSI results) electric source imaging (ESI) specifically for FCD II, including high-density EEG (HD-ESI). Some studies using ESI for localizing diagnostics for epilepsy surgery did include FCD patients ([@bb0005], [@bb2400], [@bb0170], [@bb0230], [@bb0085]). From these reports, that did include quite heterogenous etiologies, it seems that ESI can be particularily successful in FCD II-related epilepsies. However, no study so far focussed on tissue-proven FCD II. So far, only one conceptual technical analytic study compared different source localization methods from both HD-EEG and MEG for epileptic activities including clinical application on two patients reported with FCD ([@bb0105]).

Surgical strategy in FCD II is warranting a more complex approach than pure "lesionectomy" since the tissue lesion in FCD II is usually larger than seen on MRI ([@bb0260]), epileptogenicity appears not homogenously distributed within an individual FCD II lesion ([@bb0075]), and seizure onset zones could relate to parts of large FCD II only ([@bb0180] and our patient 8, see [Fig. 2](#f0010){ref-type="fig"}). The utility of surgically targeting of MEG clusters in epilepsy surgery has been suggested by earlier studies including FCD II ([@bb0275], [@bb0200], [@bb0205]). MEG seems more suitable than SPECT-techniques for highlighting FCD II related epileptogenic zones, since MEG is noninvasive, independent of a seizure, and has better properties concerning resolution in time and space ([@bb0155]). MEG data could be very helpful in cases with MRI-suspicion of FCD II but missing concordant electroclinical data, as also shown by the various patients from our cohort displaying inconclusive data by standard presurgical methods. We further suggest to integrate MEG into a diagnostic algorithm for patients presenting with "MRI-negative" epilepsy ([@bb0295], [@bb0125], [@bb0110]), especially in extratemporal epilepsies with frequent, sleep-bound seizures, since a MAP lesion in this context is highly indicative of FCD II ([@bb0210], [@bb0215]). Lesions delineated by MAP only and marked by a MEG source by this means can become eligible to a resective strategy. Patients regarded no surgical candidates using standard methods could get the chance of seizure freedom after a long duration of pharmacoresistant seizures. In summary, our data demonstrate MEG as a very strong tool in FCD II related epilepsy. A comprehensive non-invasive approach including MEG could help to achieve better outcomes in the future.
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[^1]: BS Kasper and K Rössler contributed equally.

[^2]: Electrode naming according to 10--20 system; n.a = not applicable.

[^3]: 1st MRIread refers to the initial visual MRI interpretation: +: clear-cut FCD II; (+); suspected FCD II; neg: no lesion.

[^4]: FP = fronto-polar; FM = frontal mesial; AI = antero-insular; PI = postero-insular; DLF dorso-lateral frontal; PP = postero-parietal.

[^5]: AP = antero-parietal; PM = parietal mesial; LO = lateral occipital; LT = lateral temporal; inf. = inferior; sup. = superior.

[^6]: n.a = not applicable.
